Anteris Technologies Global Corp (ASX: AVR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Anteris Technologies Global Corp Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Anteris Technologies Global Corp (ASX: AVR)
Latest News

Healthcare Shares
Two ASX healthcare shares that could be set to double

Healthcare Shares
2 ASX healthcare shares bucking the trend to hit new highs on Friday

Healthcare Shares
Anteris (ASX:AVR) share price soars 22% on successful human trial

Share Fallers
Why the Anteris (ASX:AVR) share price backtracked 6% today

Healthcare Shares
Why is the Anteris (ASX:AVR) share price surging today?

Share Market News
Anteris (ASX:AVR) share price drops 7% despite positive announcement
Share Market News
The Anteris (ASX:AVR) share price is down today but has soared 150% in 3 months

Share Market News
Why the Anteris Technologies (ASX:AVR) share price soared 23% today

Share Market News
Why the Anteris (ASX:AVR) share price will be on watch today

Share Market News
These 2 ASX healthcare shares popped today

Share Market News
Why the Anteris (ASX:AVR) share price is edging higher today
Record Highs
Twiggy Forrest backed Invex Therapeutics has now doubled since its IPO
AVR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Anteris Technologies Global Corp
Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells ADAPT & DurAVR regenerative tissue products, and researches and develops regenerative medicine and immunotherapies. The company was founded on June 23, 1999 and is headquartered in Toowong, Australia.
AVR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
16 Jul 2025 | $4.69 | $-0.24 | -4.88% | 49,987 | $4.94 | $4.94 | $4.69 |
15 Jul 2025 | $4.92 | $-0.11 | -2.19% | 25,628 | $4.94 | $5.18 | $4.92 |
14 Jul 2025 | $5.03 | $-0.26 | -4.91% | 22,351 | $5.22 | $5.35 | $5.03 |
11 Jul 2025 | $5.29 | $-0.01 | -0.19% | 13,179 | $5.40 | $5.40 | $5.20 |
10 Jul 2025 | $5.30 | $-0.30 | -5.36% | 40,979 | $5.51 | $5.52 | $5.22 |
09 Jul 2025 | $5.60 | $-0.02 | -0.36% | 8,819 | $5.62 | $5.80 | $5.51 |
08 Jul 2025 | $5.62 | $-0.23 | -3.93% | 12,488 | $5.86 | $5.86 | $5.55 |
07 Jul 2025 | $5.85 | $-0.06 | -1.02% | 2,768 | $5.91 | $6.19 | $5.85 |
04 Jul 2025 | $5.91 | $0.29 | 5.16% | 2,906 | $5.79 | $6.19 | $5.79 |
03 Jul 2025 | $5.62 | $-0.08 | -1.40% | 10,913 | $5.75 | $6.15 | $5.62 |
02 Jul 2025 | $5.70 | $-0.29 | -4.84% | 16,614 | $6.00 | $6.28 | $5.70 |
01 Jul 2025 | $5.99 | $-0.15 | -2.44% | 17,617 | $6.10 | $6.10 | $5.78 |
30 Jun 2025 | $6.14 | $-0.13 | -2.07% | 797 | $6.20 | $6.30 | $6.12 |
27 Jun 2025 | $6.27 | $0.36 | 6.09% | 17,398 | $5.93 | $6.30 | $5.91 |
26 Jun 2025 | $5.91 | $-0.21 | -3.43% | 7,430 | $6.01 | $6.08 | $5.85 |
25 Jun 2025 | $6.12 | $-0.03 | -0.49% | 2,704 | $6.21 | $6.21 | $6.00 |
24 Jun 2025 | $6.15 | $0.15 | 2.50% | 6,816 | $6.00 | $6.15 | $6.00 |
23 Jun 2025 | $6.00 | $-0.03 | -0.50% | 14,321 | $6.01 | $6.03 | $5.84 |
20 Jun 2025 | $6.03 | $0.01 | 0.17% | 8,792 | $6.00 | $6.16 | $5.80 |
19 Jun 2025 | $6.02 | $-0.03 | -0.50% | 12,995 | $6.16 | $6.29 | $5.80 |
18 Jun 2025 | $6.05 | $-0.49 | -7.49% | 15,980 | $6.55 | $6.55 | $6.05 |
17 Jun 2025 | $6.54 | $-0.11 | -1.65% | 6,103 | $6.62 | $6.62 | $6.41 |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Stephen (Steve) Denaro | Company SecretaryNon-Executive Director | Oct 2018 |
Mr Denaro has been providing company secretarial services to other ASX-listed companies since 1994 and serves as a director and sole shareholder of Trio Business Intermediaries Pty Ltd, a business consulting company, specialising in restructuring, corporate governance, directorship and company secretarial services, through which he provides these and other services. Mr Denaro has over 25 years of experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of public companies and with chartered accountancy firms in Australia and the United Kingdom. He is chair of risk management committee.
|
Mr John Seaberg | Non-Executive ChairmanNon-Executive Director | Nov 2024 |
Mr Seaberg has been serving as Board Chair of Preceptis Medical Inc since 2016 and Phraxis Medical Inc since 2009. He was Executive VP at Cedar Point Capital, a broker-dealer focused on healthcare investment from June 2015 through December 31, 2023. From 2008 until 2012, Mr Seaberg was Chair of Synovis Inc., a NASDAQ-listed manufacturer of medical device and bio scaffold tissue products which was acquired by Baxter, and, from 2007 until 2014, was Co-Founder, Chair and Chief Executive Officer of NeoChord Inc., a company commercialising technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr Seaberg served at Guidant Corp. (subsequently acquired by Boston Scientific Corp.) where he held executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In addition, Mr Seaberg was co-Founder, President and Chief Executive Officer of ACIST Medical, from 1991 to 1995. He is member of risk management committee.
|
Mr Wayne Paterson | Chief Executive OfficerManaging Director | Feb 2016 |
Mr Paterson held senior positions at Merck KGaA (Merck), a science and technology company, from 2005 to 2013, including as President of Europe, Canada and Australia, President of Emerging Markets, President of Japan and President of Cardiovascular Medicine. From 1999 until 2005, Mr Paterson served at Roche Pharmaceuticals, a multinational healthcare company, in several senior positions, including as Head of Pharmaceuticals in Roche's South Korean operation and Head of Commercial Operations for Roche China.
|
Mr David St Denis | Chief Operating OfficerPresidentNon-Executive director | Mar 2025 |
Mr Denis, has served as Chief Operating Officer of the Company since July 2017 and the Chief Executive Officer of v2vmedtech, inc. since April 2023. Mr St Denis also served as Chief Financial Officer of v2vmedtech from April 2023 to September 2023. Prior to his appointment as Chief Operating Officer of the Company, Mr St Denis served as Head of Commercial Operations for Europe and Canada at Merck since 2013, and prior to that served as Head of Operations for Emerging Markets at Merck since 2008. In addition, Mr St Denis had held multiple leadership roles at Millennium Pharmaceuticals, Inc, now Takeda Pharmaceutical Company, from 1996 to 2006, and provided strategic consulting services to such company from 2006 to 2008.
|
Mr David Roberts | Class III DirectorNon-Executive Director | Jun 2025 |
Mr Roberts currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from
1992 to 1994. |
Mr Gregory Simon Moss | Class I DirectorNon-Executive Director | Jun 2025 |
Mr Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and
Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmo's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. |
Matthew McDonnell | Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
N/A | 0 | 0.00% |